OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
OSL:PHO (5/30/2025, 7:00:00 PM)
50.2
+0.5 (+1.01%)
The current stock price of PHO.OL is 50.2 NOK. In the past month the price decreased by -5.78%. In the past year, price decreased by -23.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 53.21 | 615.27B | ||
1LLY.MI | ELI LILLY & CO | 53.16 | 614.70B | ||
ZEG.DE | ASTRAZENECA PLC | 16.47 | 395.77B | ||
1JNJ.MI | JOHNSON & JOHNSON | 15.29 | 327.71B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.27 | 327.47B | ||
NOV.DE | NOVO NORDISK A/S-B | 19.78 | 276.91B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.88 | 242.45B | ||
1SAN.MI | SANOFI | 12.22 | 228.72B | ||
SAN.PA | SANOFI | 11.38 | 213.00B | ||
SNW.DE | SANOFI | 11.38 | 212.90B | ||
NOT.DE | NOVARTIS AG-REG | 13.7 | 198.89B | ||
1MRKX.MI | MERCK & CO. INC. | 9.9 | 171.75B |
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 100
Phone: 4722062210
The current stock price of PHO.OL is 50.2 NOK. The price increased by 1.01% in the last trading session.
The exchange symbol of PHOTOCURE ASA is PHO and it is listed on the Euronext Oslo exchange.
PHO.OL stock is listed on the Euronext Oslo exchange.
8 analysts have analysed PHO.OL and the average price target is 82.88 NOK. This implies a price increase of 65.09% is expected in the next year compared to the current price of 50.2. Check the PHOTOCURE ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PHOTOCURE ASA (PHO.OL) has a market capitalization of 1.36B NOK. This makes PHO.OL a Small Cap stock.
PHOTOCURE ASA (PHO.OL) currently has 100 employees.
PHOTOCURE ASA (PHO.OL) has a support level at 49.35 and a resistance level at 50.31. Check the full technical report for a detailed analysis of PHO.OL support and resistance levels.
The Revenue of PHOTOCURE ASA (PHO.OL) is expected to grow by 11.38% in the next year. Check the estimates tab for more information on the PHO.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PHO.OL does not pay a dividend.
PHOTOCURE ASA (PHO.OL) will report earnings on 2025-07-30.
The PE ratio for PHOTOCURE ASA (PHO.OL) is 2510. This is based on the reported non-GAAP earnings per share of 0.02 and the current share price of 50.2 NOK. Check the full fundamental report for a full analysis of the valuation metrics for PHO.OL.
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL. No worries on liquidiy or solvency for PHO.OL as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS decreased by -86.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 0.4% | ||
ROA | 0.3% | ||
ROE | 0.45% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to PHO.OL. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 896.78% and a revenue growth 11.38% for PHO.OL